RecruitingPhase 2NCT03875378
Transdermal Estrogen in Women With Anorexia Nervosa
Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa
Sponsor
Pouneh K. Fazeli, MD
Enrollment
66 participants
Start Date
Aug 28, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.
Eligibility
Sex: FEMALEMin Age: 19 YearsMax Age: 45 Years
Inclusion Criteria6
- Female
- 19-45 years of age
- DSM-5 psychiatric criteria for anorexia nervosa
- <85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables
- Amenorrhea
- T-score of < -1.0 at spine or hip
Exclusion Criteria15
- Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR < 60)
- Personal history of venous or arterial clot
- History of stroke or myocardial infarction
- History of hypercoagulable disorder
- Personal history or history of a first-degree relative with breast cancer
- History of hereditary angioedema
- Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit
- Bone fracture within the prior 12 months
- Serum potassium < 3.0 meq/L, serum ALT > 3 times the upper limit of normal or Hemoglobin < 10 g/dL
- Fasting serum triglyceride level > 150 mg/dL
- Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)
- Active substance abuse
- Elevated PTH level
- 25-OH vitamin D level < 20 ng/mL
- Low phosphorus level
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTransdermal estrogen
Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
DRUGPlacebos
Placebo weekly patch
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03875378
Related Trials
Adapting Exposure for Adolescent AN
NCT071881551 location
Efficacy of a Phone-based Relapse Prevention for Anorexia Nervosa After a First Hospitalization
NCT041024756 locations
Study of Food Aversion in Patients With Anorexia Nervosa
NCT031006562 locations
Orexin Gene in Anorexia Nervosa
NCT068008981 location
Body Composition in Adolescents With Anorexia Nervosa
NCT068007421 location